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ABSTRACT
INTRODUCTION: Treatment-requiring acute non-variceal 
upper gastrointestinal bleeding (NVUGIB) is a common, 
potentially life-threatening emergency. This study 
investigated whether hospital admittance volume of 
patients with NVUGIB was associated with reduced 
mortality, reduced lasting failure of haemostatic procedures 
defined as rate of re-endoscopy with repeated haemostasis 
intervention (ReWHI), transfusion requirements and 
conversion to surgery. 
METHODS: Data on Danish nationwide admissions of 
patients with acute NVUGIB from 2011-2013 were analysed to 
estimate 30-day mortality, re-bleeding (ReWHI), transfusion 
rates and rates of conversion to surgery Data were analysed 
by regression modelling while controlling for confounders 
including age, admission haemoglobin, the American College 
of Anesthesiologists score, comorbidities and the Forrest 
classification. 
RESULTS: A total of 3,537 patients with acute non-variceal 
upper gastrointestinal bleeding were included in the study. 
The hospital admission volume of patients with NVUGIB was 
positively associated with a significant increase in ReWHI 
with an odds ratio of 1.27; p = 1.91 × 10–6. There was no 
significant association between admission volume and 
conversion to surgery, 30-day mortality or transfusion rates. 
CONCLUSIONS: A positive association between admission 
volumes of patients with NVUGIB and ReWHI was identified. 
No association between admission volumes and 30-day 
mortality or other failure of haemostasis events could be 
identified. 
FUNDING: none. 
TRIAL REGISTRATION: not applicable.
Treatment requiring acute non-variceal upper gastro-
intestinal bleeding (NVUGIB) is a common emergency 
with approximately 6,131 annual admissions in Den-
mark [1]. Advances in the pharmacological and endos-
copic treatment in recent decades have reduced re-
bleeding and the need for surgery and have therefore 
reduced mortality [2]. Despite these advances, the 30-
day mortality from NVUGIB remains approximately 10-
11% [1]. Furthermore, re-endoscopy with repeated 
haemostasis intervention (ReWHI) within five days has 
been reported to occur in upwards of 15% of cases [3, 
4].
While the 30-day mortality rate is often attributable 
to terminal malignancy, cardiopulmonary conditions 
and other comorbidities leading to multiorgan failure 
rather than actual bleeding [5], other factors besides 
comorbidity are relevant in explaining the mortality 
rate. Previous studies have shown that the mortality 
rates after surgical procedures in, e.g., pancreatic and 
colorectal cancer are significantly lower when per-
formed in hospitals with higher patient volumes [6].  
Whether patients with NVUGIB also benefit from 
admission to high-volume centres is, however, un-
known. This study investigated how the outcome of 
NVUGIB depends on the volume of patients with 
NVUGIB at the individual ce ntres in order to evaluate 
the evidence for centralisation of the treatment of 
NVUGIB.
We hypothesised that an association exists between 
hospital admission volumes of patients with NVUGIB 
and 30-day mortality rates, ReWHI, received units of 
transfused blood cells and rates of conversion to sur-
gery. 
METHODS
This study was approved by the Danish Data Protection 
Agency. The primary outcome was 30-day mortality. 
The secondary outcomes were ReWHI, units of trans-
fused red blood cells (RBC) and rates of conversion to 
surgery.
Data were retrospectively collected from 1 January 
2011 to 31 December 2013 from four different Danish 
national registries.
From the Danish National Patient Registry, we col-
lected information on all admissions where endoscopic 
haemostatic intervention was performed in the either 
the duodenum or stomach. The information included 
hospital admission info, diagnoses and comorbidities as 
well as conversion to surgery. Comorbidities were de-
fined as International Classification of Diseases, tenth 
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version (ICD10) codes indicating a diagnosis of hyper-
tension, diabetes, previous myocardial infarction, atrial 
fibrillation as well as chronic liver or renal disease
From the Danish Clinical Register of Emergency 
Surgery (Akut Kirurgi Databasen) [7], data on Ameri-
can Society of Anesthesiologists (ASA) score, admission 
haemoglobin and haemorrhage stigmata were col-
lected. Transfusion information was extracted from the 
Danish National Transfusion Database, whereas time of 
death was collected from the Danish Cause of Death 
Registry. 
Statistical analysis
Statistical analysis was performed using “R” [8].  Hos-
pitals were stratified into quartiles based on their  
annual volume of NVUGIB admissions. Data were ana-
lysed using logistical or linear regression as appro pri-
ate. Multiple regression models, associating outcomes 
with hospital NVUGIB admission volumes, were used 
and controlled for confounders, including age, sex, ad-
mission haemoglobin, ASA score, presence of comor-
bidities, as defined above, and haemorrhage stigmata 
defined as a compound grade based on the Forrest clas-
sification [9]. Grade 1 equals Forrest grades I-IIb, grade 
2 equals IIc and above.
Dichotomous outcomes such as need for ReWHI, 
conversion to surgery and 30-day mortality are pre-
sented as percentages and odds ratios (OR) with 95% 
confidence intervals (CI), whereas continuous out-
comes are reported as medians with interquartile range 
and as β-coefficients with standard error. 
Trial registration: not applicable.
RESULTS
A total of 3,537 patients with treatment-requiring acute 
NVUGIB were included. Basic demographics are pre-
sented in Table 1. 
The quantitative frequencies of the study endpoints 
are shown in Table 2. Re-bleeding occurred in 20% of 
cases, resulting in either ReWHI (16.8%) or conversion 
to surgery (2.9%). RPCs were frequent with a median 
use of four (2-7) units per patient. Fresh frozen plasma 
(FFP) and pooled platelets (PLT) were rarely employed 
with a median use of zero instances and an interquar-
tile use of (0-2) and (0-0), respectively.
TABLE 2
Quantitative frequency of the study endpoints (n = 3,537).
Failure of haemostasis and mortality, %
Need for re-endoscopy 16.8
Conversion to surgery   2.9
30-day mortality   7.2
Transfusion requirements/patient, median (IQR)
Packed red blood cells, U 4 (2-7)
Fresh frozen plasma, instances 0 (0-2)
Pooled platelets, instances 0 (0-0)
IQR = interquartile range.
TABLE 1
Basic demographics.
Age, yrs, median (IQR) 74 (65-83)
Male gender, % 56.7
Hypertension, % 53.2
Atrial fibrillation, % 25.7
Diabetes, % 17.1
Renal disease, % 11.0
Liver disease, % 6.5
Prior myocardial infarction, % 12.5
ASA score, median (IQR) 3 (2-3)
Admission haemoglobin, mmol/l, median (IQR) 5.1 (4.2-6.1)
Haemorrhage stigmataa, median (IQR) 1 (1-1)
ASA = American College of Anesthesiologists; IQR = interquartile range.
a) Compound score based on the Forrest classification: grade 1 ≈ grades  
I-IIb, grade 2 ≈ ≥ IIc.
TABLE 3
The effect of hospital admission volume of non-variceal upper gastrointestinal bleeding on study endpoints.
Unadjusted model Adjusted model
OR (95% CI) β-coefficient (± SE) p-value OR (95% CI) β-coefficient (± SE) p-value
Need for re-endoscopy 1.06 (1.03-1.09) – 9.26 × 10–5 1.28 (1.16-1.42) – 2.09 × 10–6
Conversion to surgery 0.75 (0.56-0.98) – 0.04 0.77 (0.57-1.01) – 0.06
30-day mortality 1.01 (0.91-1.13) – 0.81 0.91 (0.78-1.06) – 0.23
Packed red blood cells transfused – –0.14 (± 0.14) 0.32 – –0.17 (± 0.14) 0.21
Fresh frozen plasma transfused – –0.12 (± 0.09) 0.16 – –0.12 (± 0.08) 0.17
Pooled platelets transfused – 0.02 (± 0.03) 0.54 – 0.01 (± 0.03) 0.59
CI = confidence interval; OR = odds ratio; SE = standard error.
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The effect of NVUGIB hospital admission volume on 
study end points is presented in Table 3 and graphic-
ally depicted in Figure 1. There was no significant as-
sociation between hospital admission volume and 30-
day mortality, conversion to surgery or volume of RBCs 
transfused (Table 3).
Hospital admission volume stratification was pos i-
tively associated with a significant increase in ReWHI 
with an OR of 1.28 (95% CI: 1.16-1.42); p = 2.09 × 
10–6. 
Subgroup analysis revealed no associations be-
tween comorbidities and risk of ReWHI, although atrial 
fibrillation showed a trend towards and increased risk 
(OR = 1.28 (95% CI: 1.16-1.42); p = 0.06). In con-
trast, age (p = 0.04), ASA score (p = 0.04) and Forrest 
classification (p < 0.01) were all associated with an in-
creased risk of ReWHI. 
DISCUSSION
This study found that hospital admission volume of 
treatment-requiring patients with NVUGIB was posi-
tively associated with a significant increase in ReWHI. 
In contrast, no association with mortality, blood prod-
uct utilisation or conversion to surgery rates could be 
identified. These results suggest that ReWHIs were 
more frequent in hospitals with a high admission vol-
ume than in hospitals with a lower admission volume, 
which runs counter to the initial study hypothesis. 
Before drawing conclusions, it is important to  
underline the difference between initial technical fail-
ure of haemostasis related to inadequate haemostasis 
during the index endoscopy, and late failure, which is 
often attributed to multiple confounding variables 
(fluid resuscitation strategies, patient comorbidities, 
adherence to proton pump inhibitor regimes, etc.).  
The present study only investigated the association be-
tween NVUGIB admission volumes and the above-men-
tioned predefined outcomes, and the study setup does 
not allow for a conclusion on whether the observed dif-
ferences were primarily due to primary haemostasis in-
sufficiency, unnecessary re-endoscopies or late con-
founding effects. Furthermore, the level of adherence 
to guidelines mandating dual therapy modalities as 
well as mandatory proton inhibitor therapy cannot be 
assessed. 
Theoretically, a variety of factors could, however, 
have had an impact on the observed results. The higher 
frequency of re-endoscopy with intervention may be 
driven by the availability of dedicated endoscopy units. 
In Denmark, hospitals with a high admission volume 
often have independent endoscopy units or dedicated 
operating room (OR) facilities to which patients can 
easily be transferred without having to compete for OR 
facilities with other patient groups. When faced with a 
patient exhibiting a continuous slow drop in haemoglo-
bin levels without any signs of frank critical bleeding, 
the ease of referral to re-endoscopy may result in more 
rapidly performed re-endoscopies. 
This again raises the question of whether a sub-
group of subclinical NVUGIP re-bleedings (patients 
with a gradual drop in haemoglobin levels following 
their initial endoscopy) may actually be self-limiting, 
and suggests that a need exists for studies aimed at in-
vestigating the optimal criteria for NVUGIP re-endos-
copy. Furthermore, it may be speculated that once  
the decision to perform re-endoscopy was made, the 
threshold to proceed to actual therapeutic intervention 
was lower. As such, the easier access to re-endoscopy in 
high-volume centres may facilitate additional endos-
copies, which in turn leads to an increased number of 
interventions due to the threshold effect. Alternatively, 
confounding effects such as differences in fluid resusci-
tation strategies may also be of importance, although a 
recent study has indicated only a limited association 
between resuscitation strategy and outcomes following 
NVUGIB [10].
Another potential aspect may be the fact that high-
volume centres often also serve as academic teaching 
institutions, which may result in an increased ratio of 
trainee endoscopists, junior attendings or even resident 
physicians on call. Within the field of colorectal cancer 
surgery, surgeon volume has been found to improve 
outcomes with a reduction in 30-day mortality, five-
year survival, recurrence, anastomotic leak, hospital 
stay, operating time and hospital expenses compared 
with surgeons with a low volume of operations [5].  
FIGURE 1
The effect of hospital admission volume of non-variceal upper gastrointestinal bleeding on 
study end points graphically depicted: the average num ber of endoscopies per patient during 
admission in relation to the numbers of gastrointestinal haemorrhage admissions to the given 
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It may be speculated that these associations to some de-
gree also apply when treating patients with NVUGIB. 
While data on the experience level of the endoscopist 
would have been interesting, unfortunately such data 
were not available. 
It may also be speculated that patients in high-vol-
ume hospitals are preselected and more severely ill and 
therefore more likely to undergo re-endoscopy during 
admission than patients in hospitals with lower vol-
umes. Including comorbidities and ASA classification in 
the multivariate model did, however, not underpin 
this.
These findings contradict previous studies in the 
field. One study found a significant correlation be-
tween hospitals with low admission volume and a  
negative outcome in high-risk patients with NVUGIB 
measured on continuous bleeding after treatment, re-
bleeding during admission, the need for surgical/other 
retreatment and death within 30 days following endos-
copy [11]. Choi et al pointed out that these findings 
may be caused by the difference in the number of clips 
used, and that administration of post-endoscopy proton 
pump inhibitors was different in the two groups. While 
we cannot rule out this effect, it is important to note 
that Danish national guidelines mandate combination 
therapy, including a minimum of two modalities [12] 
(e.g., epinephrine injections, cauterisation, clips, etc.) 
as well as administration of post-endoscopy high-dose 
proton pump inhibitors. Previous reports have sug-
gested a high degree of adherence to these protocols 
[3, 4]. Furthermore, these reports do not indicate sig-
nificant differences in adherence to protocols in high- 
versus low-volume hospitals. 
Although this study does not provide adequate in-
formation to assess this, other aspects of haemostasis 
should be considered when interpreting the results: 
Novel haemostatic methods are currently under investi-
gation in order to reduce the number of re-bleedings 
and re-endoscopies in patients with NVUGIB. One 
study found that the use of haemostatic spray may be 
appropriate in high-risk patients with a peptic ulcer  
after adrenaline injection, when other haemostatic 
measures may not be technically suitable, or as an ad-
junct to conventional dual therapy in order to achieve 
primary haemostasis [13]. Other factors like transfu-
sion of PRBC was found to be associated with an in-
creased rate of re-endoscopy as well as conversion to 
surgery and in-hospital mortality in one study [10]. 
Furthermore, the timing of surgery has been found to 
be crucial in lowering in-hospital mortality. Laursen et 
al found that the optimal timing of endoscopy in hae-
mo dynamically stable patients with an ASA-score of 
3-5 is 12-36 hours post admission and that haemo-
dynamically unstable patients should undergo endos-
copy within three hours following admission [14]. 
Factors like comorbidity, but not stigmata of the bleed-
ing, have been found to be associated with a decrease 
in long-term survival [15]. 
Several studies point out and suggest predictors for 
re-bleeding after initial endoscopic interventions. One 
meta-analysis concluded that major predictors of re-
bleeding among patients with peptic ulcer bleeding in-
clude haemodynamic instability, active bleeding at  
endoscopy, large ulcer size, ulcer location, haemoglo-
bin value and the need for transfusion [16]. As such, 
several of the above-mentioned factors could have con-
founded the observed results. 
Regardless of the underlying reason, it is interesting 
to note that these factors were associated neither with 
mortality nor with transfusion requirements. As such, 
even though patients at high-volume centres required 
more ReWHI, haemostasis (as measured by blood prod-
uct utilisation) was unaffected. If the initial endoscopic 
attempt was unsuccessful, one would also have ex-
pected higher rates of blood product utilisation. In con-
trast, blood product utilisation was not associated with 
hospital admission volumes. These findings might sug-
gest that the ReWHIs performed were, to some extent, 
unnecessary, which highlights the need for further 
studies investigating the optimal indications and pro-
cedures for re-endoscopy following NVUGIB.
A number of limitations should be acknowledged in 
this study. As is the case for any retrospective study, the 
quality of the data relies solely on the quality of the in-
put data. Furthermore, we can only determine associ-
ations and not conclude on causal associations. 
We adjusted the model for relevant confounders, 
but we cannot exclude that unidentified confounders 
may be relevant to this study. Disease severities may 
not be completely captured by diagnosis codes or ASA 
classifications. Information regarding anticoagulant 
use, re-endoscopy without intervention, skill level of 
the endoscopist as well as timing of endoscopy would 
have been relevant. Also, access to interventional radi-
ology could be a factor, although referral would theor-
etically be easier from high-volume centres. Finally, 
this cohort is representative of patients with upper GI 
haemorrhage. As such, results may differ if only mas-
sive bleeders were analysed. 
Further prospective studies are relevant in order to 
assess the true causation between hospital volume and 
outcomes of NVUGIB.
CONCLUSIONS
This study found that hospital admission volume was 
positively associated with a significant increase in the 
need for re-endoscopy with intervention. This study 
found no significant association between hospital ad-
mission volume and conversion to surgery transfusion 
blood product administered or 30-day mortality.
5DANISH MEDICAL JOURNAL
Dan Med J 66/2  February 2019 
CORRESPONDENCE: Martin Sillesen. E­mail: Martin.sillesen@regionh.dk
ACCEPTED: 18 December 2018
CONFLICTS OF INTEREST: none. Disclosure forms provided by the authors 
are available with the full text of this article at Ugeskriftet.dk/dmj
LITERATURE
1. Adamsen S, de Muckadell OB. Behandling af blødende gastroduode­
nalt peptisk ulcus. Ugeskr Læger 2007;169:1551­5.
2. Wedi E, Fischer A, Hochberger J et al. Multicenter evaluation of first­
line endoscopic treatment with the OTSC in acute non­variceal upper 
gastrointestinal bleeding and comparison with the Rockall cohort: the 
FLETRock study. Surg Endosc 2018;32:307­14.
3. Danish Clinical Register of Emergency Surgery for Peptic Ulcer. Annual 
report 2015. Regionernes Kliniske Kvalitetsudviklingsprogram. Aarhus, 
Denmark, 2016.
4. Danish Clinical Register of Emergency Surgery for Peptic Ulcer. Annual 
report 2016. Regionernes Kliniske Kvalitetsudviklingsprogram. Aarhus, 
Denmark, 2017.
5. Sung JJY, Tsoi KKF, Ma TKW et al. Causes of mortality in patients with 
peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am 
J Gastroenterol 2010;105:84­9.
6. Huo YR, Phan K, Morris DL et al. Systematic review and a meta­analy­
sis of hospital and surgeon volume/outcome relationships in colo­
rectal cancer surgery. J Gastrointest Oncol 2017;8:534­46.
7. Møller MH, Larsson HJ, Rosenstock S et al. Quality­of­care initiative in 
patients treated surgically for perforated peptic ulcer. Br J Surg 
2013;100:543­52.
8. A language and environment for statistical computing. Vienna, Austria: 
Foundation for Statistical Computing, 2013. www.R­project.org/.
9. Forrest JAH, Finlayson NDC, Shearman DJC. Endoscopy in gastrointes­
tinal bleeding. Lancet 1974;304:394­7.
10. Fabricius R, Svenningsen P, Hillingsø J et al. Effect of transfusion strat­
egy in acute non­variceal upper gastrointestinal bleeding: a nation­
wide study of 5861 hospital admissions in Denmark. World J Surg 
2016;40:1129­36.
11. Choi JW, Jeon SW, Kwon JG et al. Volume of hospital is important for 
the prognosis of high­risk patients with nonvariceal upper gastro­
intestinal bleeding (NVUGIB). Surg Endosc 2017;31:3339­46.
12. Laursen SB, Jørgensen HS, Schaffalitzky de Muckadell OB. National 
consensus on management of peptic ulcer bleeding in Denmark 
2014. Dan Med J 2014;61(11):C4969.
13. Sinha R, Lockman KA, Church NI et al. The use of hemostatic spray as 
an adjunct to conventional hemostatic measures in high­risk nonvar­
iceal upper GI bleeding (with video). Gastrointest Endosc 
2016;84:900­6.e3.
14. Laursen SB, Leontiadis GI, Stanley AJ et al. Relationship between tim­
ing of endoscopy and mortality in patients with peptic ulcer bleeding: 
a nationwide cohort study. Gastrointest Endosc 2017;85:936­44.e3.
15. Malmi H, Kautiainen H, Virta LJ, et al. Outcomes of patients hospitalized 
with peptic ulcer disease diagnosed in acute upper endoscopy. Eur J 
Gastroenterol Hepatol 2017;29:1251­7.
16. García­Iglesias P, Villoria A, Suarez D, et al. Meta­analysis: Predictors 
of rebleeding after endoscopic treatment for bleeding peptic ulcer.  
Aliment Pharmacol Ther 2011;34:888­900.
